|
'''Loviride''' is an experimental antiviral drug manufactured by ] (now part of ]) that is active against ]. Loviride is a ] that entered ] clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.<ref>{{cite web | url = http://www.aidsmap.com/cms1032278.asp | title = Loviride | website = aidsmap.com | archive-url = https://web.archive.org/web/20070927192511/http://www.aidsmap.com/cms1032278.asp | archive-date = 2007-09-27 }}</ref> It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR<ref>{{cite journal | vauthors = Kroon ED, Wit FW | collaboration = CAESAR Coordinating Committee | doi = 10.1016/S0140-6736(97)04441-3 | title = Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial | journal = The Lancet | year = 1997 | volume = 349 | issue = 9063 | pages = 1413–1421 | s2cid = 20008082 | url = https://dare.uva.nl/personal/pure/en/publications/randomised-trial-of-addition-of-lamivudine-or-lamivudine-plus-loviride-to-zidovudinecontaining-regimens-for-patients-with-hiv1-infection-the-caesar-trial(60592251-8bcd-4787-8c25-b7115864937b).html }}</ref> and AVANTI<ref>{{cite journal | vauthors = Gatell J, Lange J, Gartland M | title = AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group | journal = Antiviral Therapy | volume = 4 | issue = 2 | pages = 79–86 | year = 1999 | pmid = 10682152 | doi = 10.1177/135965359900400204 | s2cid = 22443598 }}</ref>), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing ] mutations such as K103N which result in cross-class resistance to the NNRTIs ] and ]. |
|
'''Loviride''' is an experimental antiviral drug manufactured by ] (now part of ]) that is active against ]. Loviride is a ] that entered ] clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.<ref>{{cite web | url = http://www.aidsmap.com/cms1032278.asp | title = Loviride | website = aidsmap.com | archive-url = https://web.archive.org/web/20070927192511/http://www.aidsmap.com/cms1032278.asp | archive-date = 2007-09-27 }}</ref> It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR<ref>{{cite journal | vauthors = Kroon ED, Wit FW | collaboration = CAESAR Coordinating Committee | doi = 10.1016/S0140-6736(97)04441-3 | title = Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial | journal = The Lancet | year = 1997 | volume = 349 | issue = 9063 | pages = 1413–1421 | s2cid = 20008082 | url = https://dare.uva.nl/personal/pure/en/publications/randomised-trial-of-addition-of-lamivudine-or-lamivudine-plus-loviride-to-zidovudinecontaining-regimens-for-patients-with-hiv1-infection-the-caesar-trial(60592251-8bcd-4787-8c25-b7115864937b).html }}</ref> and AVANTI<ref>{{cite journal | vauthors = Gatell J, Lange J, Gartland M | title = AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group | journal = Antiviral Therapy | volume = 4 | issue = 2 | pages = 79–86 | year = 1999 | pmid = 10682152 | doi = 10.1177/135965359900400204 | s2cid = 22443598 | doi-access = free }}</ref>), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing ] mutations such as K103N which result in cross-class resistance to the NNRTIs ] and ]. |
